ReviewCureus2025
Suzetrigine as a Novel Non-opioid Analgesic Drug in Pain Management: A Review of Clinical Evidence and Therapeutic Perspectives.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07219888 (Comparison of Suzetrigine and Oxycodone for Postoperative Pain and Analgesic Requirements After Primary Total Knee Arthroplasty), which is not on this map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Comparison of Suzetrigine and Oxycodone for Postoperative Pain and Analgesic Requirements After Primary Total Knee Arthroplasty: a Prospective, Randomized Study
Who cites it
2 citing papers in PubMed.
- Selective NaV1.8 Inhibition for Pain Management: Current Evidence and Future Potential of Suzetrigine.Current pain and headache reports · 2026Review
- The real-world safety evaluation of the selective NaV1.8 inhibitor suzetrigine: disproportionality analysis and flexible empirical bayes signals from FAERS with external triangulation.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The NaV1.8 sodium channel plays a key role in the transmission of pain signals in peripheral sensory neurons. Suzetrigine is a selective NaV1.8 inhibitor developed as a non-opioid analgesic. Its action is limited to sensory neurons, reducing the risk of adverse effects associated with non-selective sodium channel blockers. Phase II and III clinical trials have demonstrated the high efficacy of suzetrigine in managing postoperative pain, along with good tolerability. Adverse events, such as dizziness or drowsiness, were rare and generally mild to moderate in intensity. The drug did not cause respiratory depression or addiction, which distinguishes it from opioids. Ongoing pharmacokinetic studies and long-term observations aim to further define the drug's safety profile and its potential use in patients with comorbid conditions. Suzetrigine may offer an effective and safe alternative to opioids in pain treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.